AURKA is a potential target for multiple myeloma therapy

Multiple myeloma (MM) is an incurable disease with the second most frequent hematopoietic malignancy. In this study, we found that the expression of Aurora kinase A (AURKA) was significantly increased in patients with high-risk multiple myeloma, especially in proliferation subgroups. MLN8237, a small molecule AURKA inhibitor, inhibited MM cell proliferation by inducing cell apoptosis and injury. Thus, we speculate MLN8237 is a potential therapeutic agent for MM and AURKA may be a potential target for MM treatment.